<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC5490823/results/search/test_trace/results.xml">
  <result pre="drug that was shown to be active against intravenous HAdV-C5" exact="infection" post="previously, is efficacious against HAdV-C6 when administered either prophylactically"/>
  <result pre="Ad epidemiology and pathology, see [3]). The symptoms of Ad" exact="infection" post="depend on the type that caused the infection; e.g.,"/>
  <result pre="happens in early childhood (ca. 60% of patients with Ad" exact="infection" post="are 5 years old or younger [4]). After recovering"/>
  <result pre="long-term immunity to that specific type. In some instances, Ad" exact="infection" post="of healthy adults can cause serious illness; certain species"/>
  <result pre="of these patients cannot eliminate the virus, and thus the" exact="infection" post="can lead to a serious, often life-threatening multi-organ illness."/>
  <result pre="transplant (HSCT) patients are especially threatened. The incidence of Ad" exact="infection" post="is between 3% and 47% for these patients, and"/>
  <result pre="the efficacy of anti-adenoviral compounds [24,25,26,27]. To mimic disseminated Ad" exact="infection" post="in immunocompromised patients, the animals are immunosuppressed by cyclophosphamide"/>
  <result pre="Ad infections. We have demonstrated that the symptoms of Ad5" exact="infection" post="in hamsters can be mitigated or even reversed with"/>
  <result pre="experiments except the repeat of the intranasal (i.n.) challenge, VGCV" exact="treatment" post="experiment. All studies were approved by the Institutional Animal"/>
  <result pre="PFU/kg of Ad6). VGCV was used at a dose and" exact="treatment" post="schedule known to be effective against Ad5 (200 mg/kg"/>
  <result pre="and eight in the Ad6-infected vehicle-treated group (Figure 1A). VGCV" exact="treatment" post="prevented mortality in both the Ad5- and Ad6-infected VGCV-treated"/>
  <result pre="weight from the onset of the study (Figure 1B). VGCV" exact="treatment" post="completely reversed body weight loss for both Ad5- and"/>
  <result pre="were normal for the Ad6-infected VGCV-treated hamsters (Figure 1C). VGCV" exact="treatment" post="mitigated liver pathology for Ad5-challenged hamsters as well, although"/>
  <result pre="with the Ad6 burden being generally higher than Ad5. VGCV" exact="treatment" post="reduced the virus burden in all three organs for"/>
  <result pre="of VGCV starting one day after challenge, and continued the" exact="treatment" post="b.i.d. for the duration of the study. There were"/>
  <result pre="animals showed liver pathology that is characteristic of disseminated Ad" exact="infection" post="in this model. VGCV treatment completely prevented mortality in"/>
  <result pre="is characteristic of disseminated Ad infection in this model. VGCV" exact="treatment" post="completely prevented mortality in the Ad6-infected VGCV-treated group. Hamsters"/>
  <result pre="weight from the onset of the study (Figure 3B); VGCV" exact="treatment" post="completely reversed this body weight loss (Figure 3B). 3.3."/>
  <result pre="Ad6 Respiratory Infection of Immunosuppressed Female and Male Hamsters Respiratory" exact="infection" post="is one of the main routes by which patients"/>
  <result pre="weight starting at 2 days post challenge (Figure 4A); VGCV" exact="treatment" post="mitigated body weight loss (Figure 4A). No body weight"/>
  <result pre="a very high virus burden in the lungs, while VGCV" exact="treatment" post="significantly reduced the virus burden (Figure 4B). To investigate"/>
  <result pre="the same kinetics as Ad6-infected females (Figure 5A), and VGCV" exact="treatment" post="had the same mitigating effect (Figure 5A). At 3"/>
  <result pre="found that at 3 and 7 days post challenge, VGCV" exact="treatment" post="decreased the virus burden in the lungs compared to"/>
  <result pre="followed by 20 mg/kg doses three times weekly), starting the" exact="treatment" post="one day before challenge. There were no treatment-related deaths"/>
  <result pre="weight from the onset of the study (Figure 6A). CDV" exact="treatment" post="significantly mitigated body weight loss (Figure 6A); however, it"/>
  <result pre="a very high virus burden in the lungs, while CDV" exact="treatment" post="may have marginally reduced the virus burden (Figure 6B)."/>
  <result pre="is also different; Ad5-infected hamsters lost more weight right after" exact="infection" post="than Ad6-infected ones; however, morbidity and mortality was greater"/>
  <result pre="most prominent site of pathogenicity for Ad5 [29]. Remarkably, VGCV" exact="treatment" post="of Ad6-infected animals reduced pathology in the liver, lungs"/>
  <result pre="undetectable levels (Figure 2). This finding opens the possibility of" exact="testing" post="the efficacy of anti-Ad compounds in the lungs and"/>
  <result pre="have shown that several drugs were active against i.v. Ad5" exact="infection" post="[24,25,26,27,35]. However, none of these drugs was effective against"/>
  <result pre="[24,25,26,27,35]. However, none of these drugs was effective against respiratory" exact="infection" post="with the virus. The presumed reason for this inefficacy"/>
  <result pre="even in CP-treated animals, much of the pathology after intranasal" exact="infection" post="with Ad5 is the result of the immune response"/>
  <result pre="Ad replication and cytopathic effect. Consistent with this hypothesis, VGCV" exact="treatment" post="of hamsters challenged intranasally with Ad6 significantly decreased body"/>
  <result pre="i.n. challenge model. As with VGCV, we found that prophylactic" exact="treatment" post="with CDV mitigated body weight loss and decreased the"/>
  <result pre="burden in the lungs was not statistically significant, and the" exact="treatment" post="did not mitigate the gross pathology observed in the"/>
  <result pre="Syrian hamster model, Ad6 challenge is a better way of" exact="testing" post="these drugs than Ad5. Further, these data confirm our"/>
  <result pre="previous finding that VGCV is very effective against disseminated Ad" exact="infection" post="in the Syrian hamster model. Adding to this, we"/>
  <result pre="this, we demonstrated that VGCV is efficacious against respiratory Ad" exact="infection" post="of hamsters. In these studies, we chose to use"/>
  <result pre="have reported previously that GCV was equally efficacious against HAdV-C5" exact="infection" post="in the hamster model [26]; thus, we believe that"/>
  <result pre="6.LynchJ.P.KajonA.E.Adenovirus: Epidemiology, global spread of novel serotypes, and advances in" exact="treatment" post="and preventionSemin. Respir. Crit. Care Med.20163758660210.1055/s-0031-128328727486739 7.IsonM.G.Adenovirus infections in"/>
  <result pre="in hematopoietic stem cell transplant recipientsBlood20101165476548510.1182/blood-2010-04-25929120837781 10.LenaertsL.de ClercqE.NaesensL.Clinical features and" exact="treatment" post="of adenovirus infectionsRev. Med. Virol.20081835737410.1002/rmv.58918655013 11.Matthes-MartinS.BoztugH.LionT.Diagnosis and treatment of"/>
  <result pre="features and treatment of adenovirus infectionsRev. Med. Virol.20081835737410.1002/rmv.58918655013 11.Matthes-MartinS.BoztugH.LionT.Diagnosis and" exact="treatment" post="of adenovirus infection in immunocompromised patientsExpert Rev. Anti-Infect. Ther.2013111017102810.1586/14787210.2013.83696424073835"/>
  <result pre="of adenovirus infectionsRev. Med. Virol.20081835737410.1002/rmv.58918655013 11.Matthes-MartinS.BoztugH.LionT.Diagnosis and treatment of adenovirus" exact="infection" post="in immunocompromised patientsExpert Rev. Anti-Infect. Ther.2013111017102810.1586/14787210.2013.83696424073835 12.SterczB.NagyK.OngradiJ.Adenovirus infections in"/>
  <result pre="from the advise study evaluating brincidofovir (bcv, cmx001) for the" exact="treatment" post="of disseminated and high-risk adenovirus (AdV) infectionProceedings of the"/>
  <result pre="trialBiol. Blood Marrow Transplant.20172351252110.1016/j.bbmt.2016.12.62128063938 21.CamargoJ.F.MorrisM.I.AbboL.M.SimkinsJ.SaneeymehriS.AlencarM.C.LekakisL.J.KomanduriK.V.The use of brincidofovir for the" exact="treatment" post="of mixed dsDNA viral infectionJ. Clin. Virol.2016831410.1016/j.jcv.2016.07.02127513204 22.VoigtS.HofmannJ.EdelmannA.SauerbreiA.KuhlJ.S.Brincidofovir clearance"/>
  <result pre="Virol.2016831410.1016/j.jcv.2016.07.02127513204 22.VoigtS.HofmannJ.EdelmannA.SauerbreiA.KuhlJ.S.Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus" exact="infection" post="after stem cell transplantationTranspl. Infect. Dis.20161879179410.1111/tid.1258227482652 23.WoldW.S.TothK.Syrian hamster as"/>
  <result pre="Chemother.2014587171718110.1128/AAC.03860-1425224011 27.TollefsonA.E.SpencerJ.F.YingB.BullerR.M.WoldW.S.TothK.Cidofovir and brincidofovir reduce the pathology caused by systemic" exact="infection" post="with human type 5 adenovirus in immunosuppressed syrian hamsters,"/>
  <result pre="oncolytic adenovirus vectorsCancer Res.2006661270127610.1158/0008-5472.CAN-05-349716452178 29.TollefsonA.E.YingB.SpencerJ.F.SagartzJ.E.WoldW.S.TothK.Pathology in permissive syrian hamsters after" exact="infection" post="with human adenovirus is the result of virus replication;"/>
 </snippets>
</snippetsTree>
